Table 1 Demographic and clinical characteristics of OROS-MPH users with ADHD in the US and Japan, by age groups
| Â | United States | Japan | ||
|---|---|---|---|---|
Child group (n = 98,973) | Adolescent group (n = 62,002) | Child group (n = 4595) | Adolescent group (n = 1508) | |
Median age at index date, years (IQR) | 9 (8–11) | 15 (14–16) | 9 (8–11) | 14 (14–16) |
Sex, n (%) | ||||
 Male | 71,559 (72.3) | 42,020 (67.8) | 3923 (85.4) | 1102 (73.1) |
 Female | 27,414 (27.7) | 19,982 (32.2) | 672 (14.6) | 406 (26.9) |
Comorbid psychiatric disordersa, n (%) | ||||
 Overall | 10,819 (10.9) | 10,439 (16.8) | 424 (9.2) | 353 (23.4) |
 Major depressive | 2466 (2.5) | 5236 (8.4) | 96 (2.1) | 220 (14.6) |
 Anxiety | 4844 (4.9) | 4647 (7.5) | 127 (2.8) | 106 (7.0) |
 Learning disorder | 1989 (2.0) | 809 (1.3) | 181 (3.9) | 66 (4.4) |
 Oppositional behavior | 2853 (2.9) | 1815 (2.9) | 30 (0.7) | 10 (0.7) |
 Substance related disorders | 32 (0.03) | 305 (0.5) | 10 (0.2) | 4 (0.3) |
Other ADHD medication users before OROS-MPHb, n (%) | ||||
 Overall | 45,558 (46.0) | 24,398 (39.4) | 786 (17.1) | 320 (21.2) |
 Psychostimulants: | ||||
  Overall | 40,248 (40.7) | 21,591 (34.8) | 23 (0.5) | 5 (0.3) |
  Other generic MPH | 23,566 (23.8) | 12,915 (20.8) | 24 (0.5) | 5 (0.3) |
  Amphetamine | 11,775 (11.9) | 5385 (8.7) | 0 | 0 |
  Other psychostimulantsc | 10,660 (10.8) | 5581 (9.0) | 0 | 0 |
 Non-psychostimulants: | ||||
  Overall | 11,815 (11.9) | 5922 (9.6) | 766 (16.7) | 317 (21.0) |
  Atomoxetine | 5978 (6.0) | 3040 (4.9) | 637 (13.9) | 282 (18.7) |
  Guanfacine | 3320 (3.4) | 1678 (2.7) | 185 (4.0) | 51 (3.4) |
  Clonidine | 3426 (3.5) | 1613 (2.6) | 0 | 0 |
  Other non-psychostimulantsd | 0 | 0 | 1 (0.02) | 9 (0.6) |